Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.65
Bid: 3.50
Ask: 3.80
Change: 0.25 (7.35%)
Spread: 0.30 (8.571%)
Open: 3.43
High: 3.65
Low: 3.43
Prev. Close: 3.40
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

26 Oct 2023 10:07

RNS Number : 4118R
Panmure Gordon (UK) Limited
26 October 2023

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader:

Panmure Gordon (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Allergy Therapeutics plc

(d) Date dealing undertaken:

25 Oct 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.1p ordinary

Purchase

887,819

0.013375

0.01316

0.1p ordinary

Sales

694,027

0.0144

0.0144

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing, or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

Date of disclosure:

26/10/2023

Contact name:

Freddie Wooding

Telephone number:

+44 (0)20 7886 2969

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FERGZMZGLVKGFZG
Date   Source Headline
22nd Sep 20087:00 amRNSFinal Results
22nd Sep 20087:00 amRNSResearch Update
22nd Aug 20083:06 pmRNSHolding(s) in Company
9th Jun 20087:00 amRNSResearch Update
14th May 20087:00 amRNSResearch Update
7th May 200811:50 amRNSDirector/PDMR Shareholding
15th Apr 20082:28 pmRNSAIM Notice 26
17th Mar 20087:01 amRNSInterim Results
14th Mar 200811:59 amRNSHolding(s) in Company
7th Mar 20081:47 pmRNSHolding(s) in Company
31st Jan 20087:00 amRNSNotice of Results
29th Jan 20084:15 pmRNSHolding(s) in Company - Amend
29th Jan 200812:42 pmRNSHolding(s) in Company
14th Jan 20087:01 amRNSChange of Adviser
27th Dec 200710:21 amRNSGrant of Options
12th Dec 200710:28 amRNSAvailability of Annual Report
29th Nov 20072:22 pmRNSResult of AGM
16th Nov 20073:31 pmRNSDirector/PDMR Shareholding
9th Nov 20073:24 pmRNSHolding(s) in Company
1st Nov 20077:02 amRNSResearch Update
29th Oct 20073:39 pmRNSHolding(s) in Company
26th Oct 20073:10 pmRNSDirector/PDMR Shareholding
11th Oct 200710:33 amRNSHolding(s) in Company
25th Sep 20077:00 amRNSFinal Results
14th Aug 20078:00 amRNSChange of Adviser
10th Aug 20079:28 amRNSAIM Rule 26
6th Aug 200711:03 amRNSHolding(s) in Company
24th Jul 200710:41 amRNSResearch Update
17th Jul 20073:36 pmRNSHolding(s) in Company
11th Jul 200710:01 amRNSClinical Update
19th Jun 200711:03 amRNSHolding(s) in Company
14th Jun 20077:01 amRNSResearch Update
8th Jun 20076:00 pmRNSAppointment of Joint Broker
29th May 20079:15 amRNSEur40 million Debt Facility
29th May 20077:02 amRNSEUR40 million Debt Facility
8th May 200710:45 amRNSHolding(s) in Company
18th Apr 20077:01 amRNSResearch Update
2nd Apr 20077:02 amRNSResearch Update
23rd Mar 200711:42 amRNSHolding(s) in Company
23rd Mar 20077:01 amRNSRe Investment
5th Mar 200712:04 pmRNSHolding(s) in Company
28th Feb 20077:01 amRNSInterim Results
27th Feb 200710:21 amRNSHolding(s) in Company
15th Feb 20072:29 pmRNSHolding(s) in Company
6th Feb 20074:46 pmRNSHolding(s) in Company
5th Feb 20073:04 pmRNSHolding(s) in Company
31st Jan 200710:18 amRNSTotal Voting Rights
31st Jan 20077:01 amRNSResearch Update
26th Jan 200710:00 amRNSOpening of Facilities
23rd Jan 20077:01 amRNSResearch Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.